Compare Summit Therapeutics Inc (SMMT) vs ThredUp Inc (TDUP) Price & Performance

Summit Therapeutics (SMMT) trades at $15.10, showing minimal daily change. The technical outlook is bullish based on moving averages, though the stock faces critical FDA review for its lead drug ivonescimab by November 2026. Recent news includes regulatory approval in China and expanded clinical trials, but the company reports significant losses and negative cash flow from operations, highlighting its pre-revenue biotech status.

The investment case hinges on ivonescimab's regulatory success, with a consensus price target of $24.18 implying substantial upside. However, high execution risk, ongoing losses, and a shareholder investigation present significant challenges. The stock offers high-risk, high-reward potential for speculative investors banking on positive clinical and regulatory outcomes.

ThredUp (TDUP) trades at $3.17, up 0.96% on the day, but remains under pressure after a significant Q2 2026 earnings miss and lowered full-year revenue guidance. The stock's technical picture is bearish, while fundamentals show improving revenue growth but persistent losses. Recent news highlights an ongoing securities investigation related to the guidance revision, contributing to negative sentiment.

The outlook is cautious. While analyst consensus is technically 'Buy' (57% of ratings), recent operational setbacks and the stock's sharp decline post-earnings suggest significant near-term risk. The primary opportunity lies in the company's high gross margins and active buyer growth, but profitability remains elusive and investor confidence is fragile.